Akihiro Ito

p300/CBP‐mediated p53 acetylation is commonly induced by p53‐activating agents and inhibited by MDM2

Akihiro Ito, Chun-Hsiang Lai, Xuan Zhao et al. · The EMBO Journal · 2001 · 575 citations · Full text

Medicine, Cancer Biology, Oncology +4

MDM2–HDAC1‐mediated deacetylation of p53 is required for its degradation

Akihiro Ito, Yoshiharu Kawaguchi, Chun-Hsiang Lai et al. · The EMBO Journal · 2002 · 566 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +11

Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract.

Kazuyoshi Yanagihara, Akihiro Ito, T Toge et al. · PubMed · 1993 · 327 citations

Medicine, Oncology, Pharmacology +10

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

Shigehira Saji, Masayo Kawakami, Shin‐ichi Hayashi et al. · Oncogene · 2005 · 259 citations

Life Sciences, Cancer Biology, Oncology +16

Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial

Akihiro Ito, Ichiro Shintaku, Makoto Satoh et al. · Journal of Clinical Oncology · 2013 · 247 citations · Full text

Medicine, Pharmacotherapy, Urology +14